MAB8704
Anti-Dengue Virus Type IV Antibody, clone 1H10-6
ascites fluid, clone 1H10-6, Chemicon®
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
ascites fluid
klon
1H10-6, monoclonal
reaktywność gatunkowa
human
producent / nazwa handlowa
Chemicon®
metody
immunofluorescence: suitable
inhibition assay: suitable (hemagglutination)
izotyp
IgG1
Warunki transportu
dry ice
Opis ogólny
Dengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.
Specyficzność
Reacts with the Dengue type 4 virus.
Immunogen
Dengue type 4 virus antigens (H241).
Zastosowanie
Detect Dengue Virus Type IV using this Anti-Dengue Virus Type IV Antibody, clone 1H10-6 validated for use in IF, HI.
Immunofluorescent assay and hemagglutination-inhibition tests.
Final working dilutions must be determined by end user.
Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Postać fizyczna
Ascites
Przechowywanie i stabilność
Maintain at -20°C for up to 12 months from date of receipt and avoid freeze/thaw cycles.
Informacje prawne
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Oświadczenie o zrzeczeniu się odpowiedzialności
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Kod klasy składowania
10 - Combustible liquids
Klasa zagrożenia wodnego (WGK)
WGK 1
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes.
Saima Khanam, Behzad Etemad, Navin Khanna, Sathyamangalam Swaminathan
The American Journal of Tropical Medicine and Hygiene null
An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S, Pilankatta R, Khanna N, Swaminathan S
Vaccine null
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.
Gentry, M K, et al.
The American Journal of Tropical Medicine and Hygiene, 31, 548-555 (1982)
Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence
Henchal, E A, et al
The American Journal of Tropical Medicine and Hygiene, 31, 830-836 (1982)
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej